Sendai Isawa Family Katsuyama Sake Brewery: SAMURAI SAKE: Reviving a 300-Year-Old Recipe
16.1.2025 06:00:00 CET | Business Wire | Press release
“RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru” New Release
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd.:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109261916/en/
Presented in a handcrafted Sendai Tansu (Photo: Business Wire)
A Legacy of Supporting Sendai's Samurai Warlord, Date Masamune
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd., which has a history of over 330 years as the official sake brewer for the Sendai Domain founded by the feudal lord Date Masamune, released RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cruon December, 2024.
This sake, crafted by unraveling a recipe from 300 years ago, achieves a quality that extracts "twice the umami components of rice" through Katsuyama Brewery's unique centrifugal pressing method. Then, through 12 years of ice aging at minus 5 degrees Celsius, this sake has reached a level of maturity brought about by time.
Shaped by Date Masamune's legacy as a samurai leader and cultural patron, Sendai embodies his vision through international exchange and crafts like Sendai Tansu. Katsuyama Sake Brewery, the Date family's official brewery for over 300 years, honors this heritage while crafting globally renowned sake.
Winner of Prestigious Sake Competitions Worldwide!
Katsuyama Sake Brewery has earned numerous accolades. Junmai Ginjo "Ken" topped the SAKE COMPETITION in 2015 and 2016 and was Champion Sake at the 2019 London IWC. That year, Junmai Daiginjo "Den" won the President Sake title at France's KURA MASTER. Flagship Junmai Daiginjo "Akatsuki" scored 95 points from Robert Parker's Wine Advocate in 2016, ranked first among 800 new sakes, and placed second in the 2024 SAKE COMPETITION Super Premium category.
An Uniquely Exceptional Sake, Reviving a 300-Year-Old Recipe
The theme "Ryoan" honors Heizaemon Isawa, the sixth-generation owner of Katsuyama Sake Brewery, who played a key role in Sendai's growth. His restoration of Zuihō-ji, the Date family's ancestral temple, preserved traditional culture. Inspired by the legacies of Masamune and Heizaemon, RYOAN LEGEND 2012 Junmai Daiginjo embodies Sendai's history, Samurai’s pride, and innovation.
Inspired by Edo-period (1603-1868) sake recipes, this sake combines tradition and innovation. Using historical methods, it amplifies umami, unlocking rice's potential for a rich, smooth finish. Made from 2012 Yamada Nishiki Special A rice, grown near Mount Izumigatake with silica-rich water, it reflects Katsuyama’s unique terroir. With centrifugal extraction and 12 years of cold aging, it achieves a perfect balance of depth, umami, and crispness.
Presented in a handcrafted Sendai Tansu, this limited release of 50 sets offers an unparalleled experience of premium rice’s sake.
RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru |
Ingredients: Rice (domestic), Rice Koji (domestic rice) |
Polishing Ratio: 35% |
Rice Variety: 100% Yamada Nishiki |
Alcohol Content: 16% |
Volume: 720ml |
Storage: Refrigerated (room temperature during transport is acceptable) |
Brewmaster: Mitsuaki Goto |
Recommended Serving Temperature: 8–14°C |
Price: ¥1,000,000 (excluding tax) |
Sales: Limited to 50 bottles |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109261916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom